LBL-051
/ Oblenio Bio, Leads Biolabs
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Treatment with LBL-051-S3, a CD3/CD19/BCMA trispecific antibody, leads to a complete loss of plasma cells and B cells with minimal cytokine release in non-human primates
(EULAR 2026)
- No abstract available
Trispecific
1 to 1
Of
1
Go to page
1